Key Takeaways
- Marginal recovery underway, steep road ahead: Q1 FY26 showed improvement on many fronts despite mark-to-market FX losses, with both standalone and consolidated EBITDA rising. Management calls the recovery "steep" but points to green shoots in OTC, international exports, and a critical European GMP approval.
- European sterile approval unlocks a new growth vector: Goa Plant-2 received European GMP approval for sterile supply on the evening before the call, a milestone that opens a previously inaccessible market, though management is not yet sizing the opportunity.
- Domestic primary sales hit by a rare double blow: Both flagship brands, Cital and Cyclopam, were impacted together in one quarter for the first time due to climate effects on the seasonal portfolio, masking healthy secondary-level growth of 10% versus the industry's 8%.
- US FDA restart begins, but revenue is a Q4 story: Two of four lines at the warning-letter-hit Goa Plant-2 are now cleared for manufacturing, yet sales from those lines have not materialized; management advises evaluating the ophthalmic business to the US only from Q4 FY26.
- What to watch next quarter: Whether the European sterile approval translates into concrete product filings and volume commitments, the pace of the remaining Goa Plant-2 remediation to invite an FDA re-audit, and any sustained uptick in domestic primary sales after the seasonal trough.
The Recovery: Green Shoots and Steep Climbs
- EBITDA improved, but from a low base: Both standalone and consolidated EBITDA rose QoQ, a marginal improvement after Q4 FY25 was severely impacted. The company's first stated intent is to claw back to its previous 11%-13% EBITDA range, though management declined to put a timeline on hitting double digits.
- Finance costs masked underlying progress: The quarter included a ~₹5.5-6 crore mark-to-market FX loss. Excluding this, the like-for-like increase in finance costs was only slight and attributable to the passage of time.
- Other expenses are being actively managed: Key cost headers under watch include advertising, lab stores, travel, and power. The company has invested in solar to ease power costs and expects other expenses as a percentage of sales to decline as the topline grows.
- R&D spend is elevated but predictable: Q1 R&D ran higher due to typical first-quarter purchases of innovative samples. Management expects to maintain R&D at 5%-5.5% of sales going forward and plans to file 4-5 products this year.
Aditi Panandikar: "Coming out of such a period is not easy, but I am happy to share that while it is a steep road to recovery, there has been marginal improvement on many fronts."
Goa Plant-2: The Pivot Point
- European sterile approval arrived: European authorities approved Goa Plant-2 for sterile product supply to Europe as of July 23, 2025, the evening before the call. The company will file more products for European markets where the opportunity looks good but is reserving any volume or revenue quantification for now.
- US FDA has cleared two of four lines: Since the last management call in late May, the US FDA gave the go-ahead to restart manufacturing on two lines at Plant-2. Ramp-up activities have begun at the site, but no sales from products manufactured on those lines have yet occurred.
- Remediation timeline is firming up: Management expects to finish most remediation work by August 2025, with updates continuing to the FDA until December 2025. From September onward, the company should be able to invite the FDA for a re-audit, and it hopes the inspection happens within this calendar year.
- Ophthalmic revenue is a Q4 FY26 story: Given the complexity of suspension products like Brinzolamide and Combigan, management explicitly guided investors to look at Q4 FY26 as the time to start evaluating the ophthalmic business to the US and its performance.
Aditi Panandikar: "Quite honestly, it is better to look at probably Q4 this year as a time for when we can start evaluating the Ophthal business to the US and its performance."
Domestic Formulations: A Tale of Two Data Sets
- Primary sales were flat, but the quarter is seasonally tough: Q1 is challenging for most companies because it follows March, a big billing month where targets are pushed. This seasonal weight between Q4 and Q1 depressed primary-level numbers.
- Secondary data tells a healthier story: Per IQVIA data, Indoco grew 10% at the secondary level versus the industry's 8%. Cyclopam grew 11.4% against a category growing below 6%, while Cital was flat in a flat category.
- Climate hit both flagship brands simultaneously: For the first time, both Cital and Cyclopam were impacted together in one quarter at the primary level, a result of climate change affecting the seasonal product portfolio. This double blow is unprecedented in the company's recent history.
- MR productivity push is underway: The company is restructuring its medical representative footprint, moving very low-productivity headquarters to a reasonable level of at least 2, and is confident of adding at least ₹25,000 per man in incremental PHY by the end of this fiscal year.
Aditi Panandikar: "This is the first time we saw both Cital and Cyclopam impacted together in one quarter at a primary level."
International Business: Exports and Semi-Regulated Markets
- Master manufacturing program is live: Phase-1 of the program rolled out in Q1 FY26, with three of the four discussed plants now fully on and manufacturing underway. This drove a more than 26% increase in international business solid oral exports over the immediately preceding quarter.
- Full rollout expected by Q3 FY26: By the end of Q2, all plants should be up and going, meaning Q3 FY26 will see the program running from day one. Efficiency gains, however, will only materialize in Phase-2 when plant capacities are fully occupied.
- Semi-regulated markets are a bright spot: Growth in these markets is driven by a brand-building model similar to India's, with uniform expansion across French West Africa, the rest of Africa, LATAM, and other parts of Asia. Management credits good demand, a revamped sales structure, new on-ground people in French West Africa, and strategic impetus from the corporate office, and is confident of sustaining the growth.
- Europe supply remains constrained, recovery expected by Q3: Europe revenue was ₹63.5 crores in Q1 despite continuing supply challenges. Management expects to overcome these by the end of Q2, with Europe bouncing back to regular supply levels by Q3.
OTC Business and Warren Remedies
- OTC delivered a breakout quarter: The OTC business grew more than 46% over the immediately preceding quarter, showing great improvement.
- Warren Remedies hit EBITDA breakeven: The subsidiary performed quite well and broke even at the EBITDA level in Q1. The company plans to infuse capital into Warren Remedies over the coming three quarters to strengthen its balance sheet.
- Marketing spend is heavy and will stay that way: The first five years of the OTC business require significant funds for digital marketing and direct consumer reach. Q1 saw slightly better results partly because some budgeted marketing spend had not yet come in, and the company declined to disclose the exact marketing expense number.
- Breakeven is a multi-year journey: Management wants to wait for a full couple of years before evaluating breakeven at Warren Remedies, signaling a long investment horizon for the OTC build-out.
Balance Sheet and Capital Allocation
- Debt repayment is on track: The company expects to repay another ~₹68 crores in loans over the remaining nine months of the fiscal year, as per its current plan.
- CAPEX is contained: Only ongoing projects at Goa Plant-2 and the API site for Warren Remedies are underway. Management does not expect more than ~₹50 crores in incremental CAPEX this year.
- FPP Holdings needs no fresh capital: The subsidiary's performance is linked to the US business; when the US improves, FPP will also improve, and no capital infusion is required.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Goa Plant-2 remediation completion | Most remediation work finished | By August 2025 |
| FDA re-audit invitation | Reach out to FDA to request inspection | From September 2025 onward |
| Master manufacturing full rollout | All plants up and running | By end of Q2 FY26 (Q3 FY26 from day one) |
| Europe supply recovery | Overcome supply challenges, return to regular supply levels | Bounce back by Q3 FY26 |
| US ophthalmic revenue evaluation | Start evaluating ophthalmic business performance to the US | Q4 FY26 |
| Loan repayment | ~₹68 crores repaid | Remaining 9 months of FY26 |
| Incremental CAPEX | Not more than ~₹50 crores | FY26 |
| R&D product filings | File 4-5 products | FY26 |
| MR productivity | Add at least ₹25,000 per man in incremental PHY | By end of FY26 |
| Warren Remedies capital infusion | Infuse capital to strengthen balance sheet | Coming 3 quarters |
| US FDA re-inspection | Hope inspection occurs | Calendar year 2025 |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Consolidated net revenue | ₹429.1 cr, vs ₹424.3 cr same quarter last year and ₹383.9 cr immediately preceding quarter |
| Standalone net revenue | ₹383.8 cr, vs ₹394.2 cr same quarter last year and ₹341.1 cr immediately preceding quarter, 12.5% growth on Q4 FY25 |
| Consolidated EBITDA margin | 4.1%, vs 11.3% same quarter last year; preceding quarter was negative |
| Standalone EBITDA margin | 3.9%, vs 13.1% same quarter last year; preceding quarter was 1% |
| Domestic formulation revenue | ₹202.8 cr, vs ₹200.2 cr same quarter last year |
| International formulation revenue | ₹139.3 cr, vs ₹157.1 cr same quarter last year |
| US business revenue | ₹28.3 cr, vs ₹48.7 cr same quarter last year |
| Europe revenue | ₹63.5 cr, vs ₹75.4 cr same quarter last year |
| Emerging markets revenue | ₹44.3 cr, vs ₹29.8 cr same quarter last year |
| API business revenue | ₹36.6 cr, vs ₹31.2 cr same quarter last year |
| OTC revenue | ₹31.6 cr, growth of more than 46% over immediate preceding quarter |
| R&D expenses | ₹21.6 cr, expected to be maintained at 5%–5.5% of sales |
| Consolidated net debt | ₹950 cr, short-term ₹350 cr and long-term ₹600 cr as of 30th June 2025, reduced by ₹21 cr from March 2025 |
| Remediation cost | ~₹4 cr per quarter |
| Incremental CAPEX expected for FY26 | ~₹50 cr |